Atopic Dermatitis

Experts on atopic dermatitis describe the burden of the disease and provide clinical insights on counseling patients who are experiencing sleep disturbances.

A panel of dermatologists discuss the heterogeneity of clinical presentations of atopic dermatitis and offer ways to reduce misdiagnosis.

This analysis compared drug survival rates of abrocitinib and dupilumab in the treatment of adults with eczema, with different benefits highlighted for both therapies.

Atopic dermatitis increases stress, depression, anxiety, and suicidal ideation, affecting patients' mental health, a recent study found.

Study finds 70% of atopic dermatitis patients using dupilumab continued for up to 5 years, but 23.8% discontinued primarily due to adverse events or ineffectiveness.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

These findings were the result of an active-comparator study, highlighting the benefits of betamethasone versus tacrolimus among patients with eczema.

This research compared the efficacy among a cohort of individuals with obesity to the general population of adult patients with eczema.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

This interview segment featured Silverberg discussing the AHEAD atopic dermatitis recommendations and their implications for clinicians and patients.

Silverberg discusses the new AHEAD recommendations for optimizing atopic dermatitis management, highlighting goals, disease severity assessments, and guidance for escalation.

In this Month in Review, the editorial team highlights major news covered in the field of dermatology, including FDA approvals, interviews, and new findings on drugs in the pipeline.

This announcement follows roflumilast’s July 9 approval for the once-daily treatment of adults and children with mild to moderate atopic dermatitis.

These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

These new phase 3 findings from ARCADIA 1 and 2 highlight the effects of nemolizumab in combination with either topical corticosteroids or topical calcineurin inhibitors.

This meta-analysis was conducted to compare the efficacy and safety of lebrikizumab to other systemic treatments for patients with atopic dermatitis.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

Christopher Bunick, MD, PhD, offers advice for clinicians treating patients with atopic dermatitis.

An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.

Christopher Bunick, MD, PhD, examines patient satisfaction upon achieving primary study endpoints in clinical trials and highlights the significance of patient-reported outcomes (PROs) in both clinical trial designs and patient care.

Shawn Kwatra, MD, discusses the durability of treatments for atopic dermatitis and provides advice for clinicians on improving patients’ quality of life.

An expert on skin conditions provides an overview of TARGET-DERM, a real-world study of patient-reported outcomes in atopic dermatitis.

Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.

An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.

An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.